Cargando…
MED19 alters AR occupancy and gene expression in prostate cancer cells, driving MAOA expression and growth under low androgen
Androgen deprivation therapy (ADT) is a mainstay of prostate cancer treatment, given the dependence of prostate cells on androgen and the androgen receptor (AR). However, tumors become ADT-resistant, and there is a need to understand the mechanism. One possible mechanism is the upregulation of AR co...
Autores principales: | Weber, Hannah, Ruoff, Rachel, Garabedian, Michael J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7875385/ https://www.ncbi.nlm.nih.gov/pubmed/33513133 http://dx.doi.org/10.1371/journal.pgen.1008540 |
Ejemplares similares
-
MED19 encodes two unique protein isoforms that confer prostate cancer growth under low androgen through distinct gene expression programs
por: Ruoff, Rachel, et al.
Publicado: (2023) -
Racial Differences in Androgen Receptor (AR) and AR Splice Variants (AR-SVs) Expression in Treatment-Naïve Androgen-Dependent Prostate Cancer
por: Khan, Farhan, et al.
Publicado: (2023) -
MAOA EXPRESSION PREDICTS VULNERABILITY FOR ALCOHOL USE
por: Cervera-Juanes, Rita, et al.
Publicado: (2015) -
Therapeutic targeting of the androgen receptor (AR) and AR variants in prostate cancer
por: Narayanan, Ramesh
Publicado: (2020) -
Phosphorylation of the Androgen Receptor by PIM1 in Hormone Refractory Prostate Cancer
por: Ha, Susan, et al.
Publicado: (2012)